Westmont, ILCIK 20507091 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
29 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Relmada Therapeutics Inc | 6.70M | $32.36M | 14.4% | +6.70M | New Position |
| 2 | Cogent Biosciences Inc | 780.0K | $27.71M | 12.4% | +780.0K | New Position |
| 3 | Maze Therapeutics Inc | 490.0K | $20.30M | 9.1% | +490.0K | New Position |
| 4 |
| Abivax SA |
| 145.0K |
| $19.55M |
| 8.7% |
| +145.0K |
| New Position |
| 5 | Kalvista Pharmaceuticals Inc | 700.0K | $11.30M | 5.0% | +700.0K | New Position |
| 6 | Palisade Bio Inc | 4.50M | $10.57M | 4.7% | +4.50M | New Position |
| 7 | Edgewise Therapeutics Inc | 350.0K | $8.69M | 3.9% | +350.0K | New Position |
| 8 | Inhibikase Therapeutics Inc | 4.22M | $8.66M | 3.9% | +4.22M | New Position |
| 9 | Kodiak Sciences Inc | 291.7K | $8.16M | 3.6% | +291.7K | New Position |
| 10 | Terns Pharmaceuticals Inc | 190.0K | $7.68M | 3.4% | +190.0K | New Position |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio